[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100194164":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":48,"responsibleParty":79,"collaborators":42,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":42,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"hyperglycemic clamp-Meal tolerance test","EXPERIMENTAL","these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls",[13],"Drug: exendin-(9-39)",{"label":15,"type":10,"description":16,"interventionNames":17},"Labeled meal tolerance test","The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test",[18],"Drug: exendin -(9-39)",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","exendin-(9-39)","hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion",[9],[26],"no other name for exendin-(9-39)",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"exendin -(9-39)","2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.",[15],[26],[33],{"name":34,"affiliation":35,"role":36},"Marzieh Salehi, MD,MS","Marzieh Salehi","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Marzieh Salehi, MD MS","CONTACT","210-567-6691",null,"salehi@uthscsa.edu",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Jennifer Foster, MSN","210-450-8696","fosterj6@uthscsa.edu",[49,67],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Texas Diabetes Institute - University Health System","RECRUITING","San Antonio","Texas","78207","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-98.49363,29.42412,{"lat":61,"lon":60},[64,65],{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},{"name":66,"role":40,"phone":41,"phoneExt":42,"email":43},"Marzieh Salehi, MD, MS",{"facility":68,"status":51,"city":52,"state":53,"zip":69,"country":55,"countryCode":56,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"South Texas Veterans Health Care System","78229",{"type":58,"coordinates":71},[60,61],{"lat":61,"lon":60},[74,75,77],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"name":76,"role":40,"phone":46,"phoneExt":42,"email":47},"Jennifer Foster",{"name":78,"role":36,"phone":42,"phoneExt":42,"email":42},"Marzieh Salehi, MD",{"type":80,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100194164","early-phase-1-glucagon-like-peptide-1-glucose-metabolism-and-gastric-bypass-100194164",false,"NCT01803451","Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass","The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery","GLP-1","Inclusion Criteria:\n\n* age 18-65\n* healthy control without diabetes or active organ disease\n* Individuals with bariatric surgery\n* recurrent hypoglycemia post gastric bypass\n\nExclusion Criteria:\n\n* pregnancy\n* significant anemia\n* diabetes currently unless pre-op for bariatric surgery procedure\n* GI obstruction",true,"ALL","18 Years","65 Years",{"count":94,"type":95},80,"ESTIMATED","INTERVENTIONAL",[98],"EARLY_PHASE1","The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.\n\nThe central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.\n\n1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp.\n2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.\n3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.",[101],"Post-bariatric Surgery",[103,104,105],"gastric bypass","glucose metabolism","hypoglycemia","2025-09-08",{"date":108,"type":109},"2025-09-09","ACTUAL",{"date":111,"type":42},"2005-11",{"date":113,"type":95},"2027-08",{"name":5,"class":6},2]